{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05536414",
            "orgStudyIdInfo": {
                "id": "405-201-00062"
            },
            "organization": {
                "fullName": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder",
            "officialTitle": "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Extended-release Capsules as Monotherapy or as Adjunct to SSRI in Adult Subjects With Major Depressive Disorder",
            "acronym": "JUNIPER",
            "therapeuticArea": [
                "Other"
            ],
            "study": "trial-of-centanafadine-efficacy-and-safety-as-monotherapy-or-as-adjunct-to-ssri-in-adults-with-major-depressive-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-09-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-01-17",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01-17",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-07",
            "studyFirstSubmitQcDate": "2022-09-07",
            "studyFirstPostDateStruct": {
                "date": "2022-09-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-20",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD).\n\nThe trial will evaluate the efficacy and safety of centanafadine QD XR capsules as monotherapy or as adjunct to the selective serotonin reuptake inhibitor (SSRI), escitalopram."
        },
        "conditionsModule": {
            "conditions": [
                "Major Depressive Disorder"
            ],
            "keywords": [
                "MDD",
                "Centanafadine",
                "SSRI",
                "Depressive Disorder",
                "Depression",
                "Depressive Disorder, Major",
                "Mood Disorders",
                "Mental Disorders",
                "Behavioral Symptoms"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 336,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Centanafadine + Placebo",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Centanafadine",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Centanafadine + Escitalopram",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Centanafadine",
                        "Drug: Escitalopram"
                    ]
                },
                {
                    "label": "Escitalopram + Placebo",
                    "type": "ACTIVE_COMPARATOR",
                    "interventionNames": [
                        "Drug: Escitalopram",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Placebo + Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Centanafadine",
                    "description": "capsule",
                    "armGroupLabels": [
                        "Centanafadine + Escitalopram",
                        "Centanafadine + Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Escitalopram",
                    "description": "capsule",
                    "armGroupLabels": [
                        "Centanafadine + Escitalopram",
                        "Escitalopram + Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "capsule",
                    "armGroupLabels": [
                        "Centanafadine + Placebo",
                        "Escitalopram + Placebo",
                        "Placebo + Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total score.",
                    "timeFrame": "Baseline, Week 6"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Male and Female subjects between 18-65 years of age, with a primary diagnosis of major depressive disorder and in a current major depressive episode.\n* History of an inadequate response to at least 1 and no more than 3 antidepressant treatments in the current major depressive episode.\n\nKey Exclusion Criteria:\n\n* Subjects who report an inadequate response to more than 3 antidepressant treatments in the current episode.\n* Subjects with a lifetime history of schizophrenia spectrum or other psychotic disorder, bipolar or related disorder, neurocognitive disorder, or personality disorder.\n* Subjects with a current diagnosis of post-traumatic stress disorder, obsessive compulsive disorder, panic disorder, or eating disorder (including anorexia nervosa or bulimia).\n* Sexually active subjects, who could become pregnant, not agreeing to practice 2 sponsor approved methods of birth control or remain abstinent during the trial and for 30 days (females) or 90 days (males) after last dose of study drug.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Otsuka Call Center",
                    "role": "CONTACT",
                    "phone": "844-687-8522",
                    "email": "OtsukaUS@druginfo.com"
                }
            ],
            "locations": [
                {
                    "facility": "For additional information regarding sites, contact 844-687-8522",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78754",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "CSR"
            ],
            "timeFrame": "Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.",
            "accessCriteria": "Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/",
            "url": "https://clinical-trials.otsuka.com"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003866",
                    "term": "Depressive Disorder"
                },
                {
                    "id": "D000003863",
                    "term": "Depression"
                },
                {
                    "id": "D000003865",
                    "term": "Depressive Disorder, Major"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7058",
                    "name": "Depression",
                    "asFound": "Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7061",
                    "name": "Depressive Disorder",
                    "asFound": "Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7060",
                    "name": "Depressive Disorder, Major",
                    "asFound": "Major Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000089983",
                    "term": "Escitalopram"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017367",
                    "term": "Selective Serotonin Reuptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7104",
                    "name": "Dexetimide",
                    "relevance": "LOW"
                },
                {
                    "id": "M17983",
                    "name": "Citalopram",
                    "relevance": "LOW"
                },
                {
                    "id": "M2732",
                    "name": "Escitalopram",
                    "asFound": "Length",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "relevance": "LOW"
                },
                {
                    "id": "M19649",
                    "name": "Selective Serotonin Reuptake Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnDyAg",
                    "name": "Anti-Dyskinesia Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                }
            ]
        }
    },
    "hasResults": false
}